Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Uncertainty Looms For Ziopharm After Patient Death

Executive Summary

A death was reported in the company's early-stage gene therapy trial. It has not been determined yet whether the death was related to the drug and what the next steps for the company are.

You may also be interested in...



Can FDA's Breakthrough Program Finally Midwife Gene Therapy?

The often-troubled field is showing promise, and the extra resources that breakthrough designation will bring to two candidates could be what gene therapy needs to move from the theoretical to the marketable.

Update: Ziopharm Study Death Not Due To Drug

The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.

Juno ROCKETs On Fast Clinical Hold Resolution

The FDA lifted a clinical hold on the Phase II ROCKET clinical trial for Juno's lead CAR-T therapy candidate JCAR015 less than a week after it was instituted, allowing the company to proceed without using fludarabine in a pre-conditioning chemotherapy regimen.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC096914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel